Detalhe da pesquisa
1.
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Nat Commun
; 15(1): 1700, 2024 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402224
2.
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models.
Cancers (Basel)
; 15(16)2023 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37627223
3.
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5ß1: part 1.
Bioorg Med Chem Lett
; 22(12): 4111-6, 2012 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22575869
4.
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5ß1: part 2.
Bioorg Med Chem Lett
; 22(12): 4117-21, 2012 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22572578
5.
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Cancer Res
; 82(6): 1140-1152, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35078817
6.
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
J Immunother Cancer
; 10(4)2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35387780
7.
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Clin Cancer Res
; 28(20): 4536-4550, 2022 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921524
8.
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition.
Mol Cancer Ther
; 20(6): 1080-1091, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785652
9.
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.
Clin Cancer Res
; 26(23): 6335-6349, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32943458
10.
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Mol Cancer Ther
; 19(1): 13-25, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31534013
11.
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery.
J Immunother Cancer
; 7(1): 328, 2019 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31779705
12.
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.
Oncotarget
; 10(27): 2586-2606, 2019 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31080552
13.
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Mol Cancer Ther
; 18(5): 909-919, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30872381
14.
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity.
Oncoimmunology
; 7(8): e1458810, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30221055
15.
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity.
J Immunother Cancer
; 6(1): 158, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30587236
16.
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Clin Cancer Res
; 24(20): 5153-5164, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29941481